Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

15.0K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.0K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

4.4K
4.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

464
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
464
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

10.9K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

18.2K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
18.2K
What is Natural Selection?01:32

What is Natural Selection?

126.2K
Natural selection is an evolutionary process in which individuals with survival-promoting traits reproduce at higher rates. These favorable traits become more common within a population or species. Naturally selected traits initially arise via random genetic mutations. In order for selection to occur, there must be variation within a population, the trait controlling the variation must be heritable, and there must be an evolutionary advantage for variation in the trait.
126.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthesis and Target Identification of a Novel Electrophilic Warhead, 2-Chloromethylquinoline.

Biochemistry·2019
Same author

Effects of rigidity on the selectivity of protein kinase inhibitors.

European journal of medicinal chemistry·2018
Same author

A Chemical-Genetic Approach Reveals the Distinct Roles of GSK3α and GSK3β in Regulating Embryonic Stem Cell Fate.

Developmental cell·2017
Same author

A Viral Deamidase Targets the Helicase Domain of RIG-I to Block RNA-Induced Activation.

Cell host & microbe·2016
Same author

Synthesis, docking simulation, biological evaluations and 3D-QSAR study of 5-Aryl-6-(4-methylsulfonyl)-3-(metylthio)-1,2,4-triazine as selective cyclooxygenase-2 inhibitors.

Bioorganic & medicinal chemistry·2013
Same author

Synthesis, cytotoxic evaluation and molecular docking study of 2-alkylthio-4-(2,3,4-trimethoxyphenyl)-5-aryl-thiazoles as tubulin polymerization inhibitors.

Bioorganic & medicinal chemistry·2013
Same journal

Semisynthesis of Mycothiazole Analogs having Distinct Bioactivity.

ACS medicinal chemistry letters·2026
Same journal

Investigation on the Cytotoxicity of Hydroxycinnamic and Hydroxybenzoic Acid-Based Natural Antioxidant Conjugated Terpyridine Analogues toward Triple-Negative Breast Cancer.

ACS medicinal chemistry letters·2026
Same journal

Beyond Neddylation Inhibition: X‑ray Structures Reveal Carbonic Anhydrase Isoform Selectivity of Pevonedistat.

ACS medicinal chemistry letters·2026
Same journal

Structure-Guided Discovery of Selective Polo-Like Kinase 3 Inhibitors.

ACS medicinal chemistry letters·2026
Same journal

Controlling Neuroplasticity Across Scales: Constrained Serotonergic Agonists, Neuroplastogens, and Adaptive Neuromodulation.

ACS medicinal chemistry letters·2026
Same journal

Degradation and Detection: Integrating BCL6 Targeted Protein Degradation with Biomarker-Guided BET Inhibition in Cancer.

ACS medicinal chemistry letters·2026
See all related articles

Related Experiment Video

Updated: Jan 22, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.5K

Rigidification Dramatically Improves Inhibitor Selectivity for RAF Kinases.

Amir Assadieskandar1, Caiqun Yu1, Pierre Maisonneuve2

  • 1Loker Hydrocarbon Research Institute & Department of Chemistry, University of Southern California, Los Angeles, California 90089, United States.

ACS Medicinal Chemistry Letters
|July 18, 2019
PubMed
Summary
This summary is machine-generated.

Researchers developed a new strategy using inhibitor rigidification to significantly enhance selectivity for RAF kinases, a key target in cancer drug development. This approach shows promise for creating more effective cancer therapies.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.3K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.6K

Related Experiment Videos

Last Updated: Jan 22, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.5K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.3K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.6K

Area of Science:

  • Medicinal Chemistry
  • Molecular Biology
  • Oncology

Background:

  • RAF kinases are crucial cancer drug targets.
  • Current inhibitors often target the inactive RAF kinase state.
  • Previous work showed inhibitor rigidification can improve RAF kinase selectivity.

Purpose of the Study:

  • To investigate if rigidification of a different pyrazolopyrimidine scaffold can enhance RAF kinase selectivity.
  • To characterize the binding mode of the optimized inhibitor.
  • To evaluate the anti-cancer efficacy of the optimized inhibitor in cell lines.

Main Methods:

  • Inhibitor design and synthesis involving ring closure for rigidification.
  • Kinase selectivity screening against a panel of kinases.
  • X-ray crystallography to determine inhibitor-bound kinase structure.
  • Cell proliferation assays using cancer cell lines.

Main Results:

  • A novel pyrazolopyrimidine-based inhibitor (2l) demonstrated dramatically improved selectivity for RAF kinases.
  • Crystal structure revealed inhibitor 2l binds to an active-like BRAF conformation.
  • Inhibitor 2l selectively inhibited proliferation of BRAFV600E-mutant cancer cell lines.

Conclusions:

  • Inhibitor rigidification is a potent strategy for achieving high selectivity against protein kinases.
  • This approach may offer new therapeutic opportunities for cancer treatment.
  • The optimized inhibitor 2l shows potential as a targeted cancer therapy.